Navigation Links
Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies
Date:1/23/2008

CHAPEL HILL, N.C., Jan. 23 /PRNewswire/ -- Marketers, who have the primary responsibility for communicating the results of clinical trials, see coordination and timing activities as top challenges for pharmaceutical companies when communicating trial data. One interviewed marketing executive states, "we have to worry about competitors stealing your thunder, but also worry about physicians forgetting what our trial was about."

According to a Best Practices, LLC benchmarking study, the marketing team creates preliminary communication plans to create a memorable identity linking study results to the product and to identify target audiences, key messages and effective activities for disseminating the study results long before the study even begins.

Download a complimentary research summary including sample best practices and data charts at http://www3.best-in-class.com/rr902.htm.

Planning and communication tactics along with other key strategies for optimizing the likelihood of a drug's market success are compiled in the benchmarking report, "From Breakthrough to Blockbuster: Best Practices in Communicating Clinical Trial Results."

The report presents the lessons learned and best practices gleaned from survey responses and interviews with pharmaceutical executives at world-class companies, including Abbott, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Schering-Plough and Wyeth. In the report, executives reflect upon the critical steps to communicating clinical trial results to diverse physician, managed care, investor and consumer audiences. Specifically the report examines the following areas:

-- Establishing a landmark clinical study

-- Choosing winning tactics for communicating study findings to

physicians, managed care organizations, investors and consumers

-- Avoiding the "cl
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ...cal documentation services, today announced that i...ns, Inc. (Nuance) under which MedQuist will now li...ne and processing software for use in SpeechQ of G...ecognition application for all medical disciplines...
(Date:11/30/2009)...ewswire/ -- StemCyte, Inc. concluded an exclusive ...mia Sinica, the National Laboratory of Taiwan, for...erty (IP) related to the treatment of Chronic Stro...red by a team led by Professor John Lin, MD, PhD a...urrently the exclusive collaborator with StemCyte ...
(Date:11/30/2009)...swire/ -- Reportlinker.com announces that a new ma...: ,, Inflammatory Disorders: Therapies That Su...://www.reportlinker.com/p0165600/Inflammatory-Diso...e-Response.html ,, The human immune system can...roducing an exaggerated response to a foreign subs...
Breaking Medicine Technology:MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 1Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 4LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidates Inscrybe Healthcare 55110 1LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidates Inscrybe Healthcare 55110 2LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidates Inscrybe Healthcare 55110 3LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidates Inscrybe Healthcare 55110 4Just Out 3A A Little Piece of Paper That Helps Stop the Spread of Flu 21 55108 1Just Out 3A A Little Piece of Paper That Helps Stop the Spread of Flu 21 55108 2
...nisone arm demonstrated a, significant survival b..., CAMBRIDGE, Mass., Aug. 27 Millennium: The Take...n of results from the 682,patient, randomized, Pha...e,New England Journal of Medicine. The results sho...t complete remission (CR) rate with VELCADE,melpha...
...at The Children,s Hospital at, Montefiore Provid...and Specialty Services, ... Every Heart Condition, NEW YORK, Aug. 27 The Ch... the medical miracle of pediatric heart,transplant...of its,transplant center application by the New Yo...
Other Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4
(Date:12/1/2009)...ever published study of aviation-related injuries ...patients are admitted to U.S. hospitals with aviat...on-deaths occur each year. The study, conducted by...ol of Public Health,s Center for Injury Research a...at the largest categories of patients were occupan...
(Date:11/30/2009)...CHICAGO, Dec. 1 Results of a rando...t the annual meeting of the Radiological Society o...ients with narrowing or blockage in arteries that ...dy also have significant but silent coronary arter...) occurs when plaque, a combination of fat, choles...
(Date:11/30/2009)...CHICAGO, Dec. 1 Low-dose radiation...east cancer risk in women with genetic or familial...tudy presented today at the annual meeting of the ..., "For women at high risk for breast cancer, scre...ould be taken when considering mammography for scr...
(Date:11/30/2009)..., WAYNE, Pa., Nov. 30 ...: A0YCND) has elected William "Bill" R. Fields to...ds, age 59, is Chairman of Intersource Co. Ltd. Mr...nc. Previously, Mr. Fields served as Chairman and .... from 2002 to 2003, President and Chief Executive...
(Date:11/30/2009)...WASHINGTON, Nov. 30 At ...nizations (LCAO) and the Consortium for Citizens w...President of Public Policy and Advocacy for NCOA, ...rm legislation responds to the growing crisis in l...es. ,, "Millions of seniors, after working hard...
Breaking Medicine News(10 mins):Health News:More than 1,000 patients in US admitted annually for aviation-related injuries 2Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 2Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 3Health News:Mammography May Increase Breast Cancer Risk in Some High-Risk Women 2Health News:Mammography May Increase Breast Cancer Risk in Some High-Risk Women 3Health News:VitaminSpice Elects Bill Fields to the Board of Directors 2Health News:NCOA, Bedlin Brief Leading Aging Organizations on Health Care Reform, Needed Long-Term Care Provisions 2
...YSE: APD ) today announced it has sold three of ...litan, Inc. (LMI), the largest provider of durable...ces in the northeast, based in Mount Vernon, N.Y. ...t of the Air Products Healthcare LLC Group, namely...
... on May 13, 2009, as Minnesota became the first st...l health provider into state statute - enabling st...Hygiene Practitioner (ADHP) model to become licens...ntal Therapist providers in the state. Minnesota G...
...ce 2006 , , DETROIT, May 18 A just-completed fin... by the Michigan Office of Financial and Insurance... financial statements over the audit,s four-year p...nded by the National Association of Insurance Comm...
...echnologies ( www.epeiusbiotech.com ) today anno...in-G, a tumor-targeted anti-cancer agent designed ...ve spread throughout the body. While Rexin-G is cu...I studies and a Phase II confirmatory trial in the...
...op the growth of new blood vessels has produced dr...thyroid cancer, research from Mayo Clinic indi...n Society of Clinical Oncology (ASCO), Mayo inve...topped growing, or quickly shrank. , , The patie...
...ew Malady Can Be Cured , , WASHINGTON, May 18 Th...for other, less serious ailments. But thanks to a ...velopment Association (ARDA), more people are gett...ing to a recent survey conducted on ARDA,s consume...
Other Medicine News:Health News:Air Products Sells Three U.S. Healthcare Businesses to Landauer-Metropolitan 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:State Audit of Blue Cross Blue Shield of Michigan Shows Company in Compliance with State and National Accounting Guidelines 2Health News:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 2Health News:Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report 2Health News:Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report 3Health News:Don't Let Your Summer Vacation Be Threatened by 'Guilty Vacation Syndrome' 2
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: